Biosplice Therapeutics

Biosplice Therapeutics is a biotechnology company focused on developing first-in-class therapies that harness alternative splicing, a fundamental biological process that regulates the production of proteins. The company's mission is to restore health by targeting the CLK/DYRK family of kinases, which govern the selection of tissue-specific and disease-selective RNA splice-sites, defining them as druggable targets within the "command and control" center of proteome diversification. Biosplice has built a clinical pipeline focused on osteoarthritis and oncology, with early-stage programs in neurology and other areas of significant unmet medical need.

The company's approach to drug development leverages the broad therapeutic potential of alternative splicing modulation in various disease areas. Biosplice has established clinical proof-of-concept for therapeutic modulation of alternative splicing with the development of lorecivivint, targeting osteoarthritic disease progression. Their oncology efforts center on pan-CLK and DYRK inhibition for therapeutic modulation of alternative splicing, with Cirtuvivint (SM08502) as a lead clinical asset. Biosplice's innovative approach has garnered significant attention, attracting investments and collaborations with leading pharmaceutical companies.

Biosplice Therapeutics' mission is to restore health by developing innovative therapies that target alternative splicing, a fundamental biological process that governs tissue specialization and protein production. The company's platform leverages unique chemical entities that modulate alternative splicing, specifically targeting CLK/DYRK family kinases, which play a critical role in regulating gene expression and cellular behavior. This approach aims to selectively eliminate harmful proteins and reprogram cellular function, leading to potentially curative treatments for diseases with significant unmet medical needs, particularly in osteoarthritis, oncology, and neurology.

Biosplice promotes a collaborative and integrated team culture, emphasizing shared vision, values, and accountability. They operate in a fully-integrated, no-silo team structure, fostering a sense of unity and shared responsibility across the company. This approach aims to encourage open communication, shared decision-making, and a strong sense of ownership among employees.

Biosplice Therapeutics strives to foster a diverse and inclusive workplace where all employees feel valued, respected, and empowered to contribute their unique perspectives. They believe that a diverse workforce leads to better decision-making, innovation, and a more positive work environment. They aim to create a culture of equity where everyone has the opportunity to succeed regardless of their background, identity, or experience.